Security
ANIX · Anixa Biosciences Inc
ANIXNASDAQCommon stockCurrentCIK 715446Updated Sep 25, 2026
Name history
ITUS Corp · through Sep 27, 2018COPYTELE INC · through Aug 27, 2014
ANIX price & chart
Loading TradingView…
NASDAQ:ANIX on TradingView ↗In the news
Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones News provided by Anixa Biosciences, Inc. May 19, 2025, 08:00 ET Share this article Share to X Share this article Share to X SAN JOSE, Calif. , May 19, 20 ↗
Recent filings
10-Q filing
10-Q filing
Submission of Matters to a Vote of Security Holders · Regulation FD Disclosure
Items 5.07, 7.01, 9.01
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 16,080,000Source | 21,591,000Source | 25,522,000Source | 30,412,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,244,000Source | 1,271,000Source | 915,000Source | 12,360,000Source |
| Assets, CurrentUSD | 15,887,000Source | 21,362,000Source | 25,356,000Source | 30,200,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 713,000Source | 1,265,000Source | 1,242,000Source | 513,000Source |
| Operating Lease, Right-of-Use AssetUSD | 193,000Source | 229,000Source | 166,000Source | 212,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,130,000Source | 2,703,000Source | 2,151,000Source | 2,212,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 330,000Source | 322,000Source | 311,000Source | 309,000Source |
| Additional Paid in CapitalUSD | 266,508,000Source | 260,432,000Source | 252,222,000Source | 247,123,000Source |
| Retained Earnings (Accumulated Deficit)USD | -251,677,000Source | -240,750,000Source | -228,196,000Source | -218,385,000Source |
| Stockholders' Equity Attributable to ParentUSD | 15,161,000Source | 19,998,000Source | 24,337,000Source | 29,047,000Source |
| Liabilities and EquityUSD | 16,080,000Source | 21,591,000Source | 25,522,000Source | 30,412,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,967,000Source | 2,500,000Source | 2,028,000Source | 2,037,000Source |
| Operating Lease, Liability, CurrentUSD | 41,000Source | 29,000Source | 52,000Source | 46,000Source |
| Accounts Payable, CurrentUSD | 165,000Source | 525,000Source | 206,000Source | 265,000Source |
| Operating Lease, Liability, NoncurrentUSD | 163,000Source | 203,000Source | 123,000Source | 175,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -1,211,000Source | -1,110,000Source | -966,000Source | -847,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,761,000Source | 1,946,000Source | 1,770,000Source | 1,726,000Source |
| Short-term InvestmentsUSD | 13,930,000Source | 18,653,000Source | 22,929,000Source | 17,327,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -11,028,000Source | -12,698,000Source | -9,930,000Source | -13,771,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,681,000Source | 4,420,000Source | 4,422,000Source | 6,000,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -360,000Source | 319,000Source | -59,000Source | 129,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -7,173,000Source | -7,335,000Source | -6,209,000Source | -6,492,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 4,866,000Source | 4,276,000Source | -5,602,000Source | -10,728,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | 6,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 2,280,000Source | 3,415,000Source | 366,000Source | 452,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -27,000Source | 356,000Source | -11,445,000Source | -16,768,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | 23,000Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 6,630,000Source | 7,435,000Source | 6,291,000Source | 7,172,000Source |
| Net Income (Loss) Attributable to ParentUSD | -10,927,000Source | -12,554,000Source | -9,811,000Source | -13,595,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -101,000Source | -144,000Source | -119,000Source | -176,000Source |
| Operating Costs and ExpensesUSD | 7,891,000Source | 9,049,000Source | 6,486,000Source | 7,220,000Source |
| Proceeds from Issuance of Common StockUSD | 2,378,000Source | 2,955,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | 456,000Source | 353,000Source | 439,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | 210,000Source | 210,000Source | — |
| Operating Income (Loss)USD | -11,701,000Source | -13,831,000Source | -11,011,000Source | -13,875,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -101,000Source | -144,000Source | -119,000Source | -176,000Source |
| Net Income (Loss) Attributable to ParentUSD | -10,927,000Source | -12,554,000Source | -9,811,000Source | -13,595,000Source |
| Earnings Per Share, BasicUSD per share | -0.34Source | -0.39Source | 0.32Source | -0.45Source |
| Earnings Per Share, DilutedUSD per share | -0.34Source | -0.39Source | 0.32Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 32,454Source | 31,898Source | 30,980Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 32,454Source | 31,898Source | 30,980Source | 30,374,000Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 11,701,000Source | 13,831,000Source | 11,221,000Source | 13,875,000Source |
| General and Administrative ExpenseUSD | 6,630,000Source | 7,435,000Source | 6,291,000Source | 7,172,000Source |
| Interest Income, OtherUSD | 673,000Source | 1,133,000Source | 1,081,000Source | 104,000Source |
| Operating Costs and ExpensesUSD | 7,891,000Source | 9,049,000Source | 6,486,000Source | 7,220,000Source |
| Research and Development ExpenseUSD | 5,071,000Source | 6,396,000Source | 4,769,000Source | 6,703,000Source |
Filing attachments
ex99-1.htm · 8-K · 2026-02-09
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higher Trial expansion reflects growing confidence in intra-peritoneal CAR-T delivery and introduces lymphodepletion to potentially enhance…
Read attachment ↗ex99-1.htm · 8-K · 2025-12-12
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose Results Support Advancement of the Program into Phase 2 Development Combination of Keytruda® and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 …
Read attachment ↗